YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Mineralys Therapeutics, Inc. RADNOR, Pa., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse ou…
Mineralys Therapeutics, Inc. Q2 2026 Earnings Call Summary - Moby Strategic Positioning and Clinical Differentiation Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you w…
Key Points Interested in Mineralys Therapeutics, Inc.? Here are five stocks we like better. Mineralys is preparing for a potential lorundrostat launch ahead of the FDA's Dec. 22 PDUFA target date for uncontrolled hypertension, with regulat…
David Malcom Rodman, the chief medical officer at Mineralys Therapeutics, Inc. (NASDAQ:MLYS), executed a sale of 20,407 shares of common stock on July 13 and July 15, 2026, for a total value of $557,000, according to an SEC Form 4 filing.…
Key Points The executive sold 20,407 shares at a weighted average price of $27.28 per share, totaling approximately $557,000 in gross proceeds. The disposition was structured as a simultaneous exercise of 20,407 stock options and an immedi…
Chief Executive Officer Jon Congleton reported a sale of 10,700 shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) on July 13, 2026, according to an SEC Form 4 filing. Transaction summary Metric Value Shares sold (directly held) 10,700 T…
Key Points The CEO of Mineralys reported selling 10,700 shares for $291,468 on July 13, 2026. The transaction reduced direct common stock holdings by 2%, as reported in the Form 4. The sale was executed pursuant to a Rule 10b5-1 trading pl…
Mineralys Therapeutics Inc. (NASDAQ:MLYS) is one of the 8 Hidden Multibagger Stocks to Buy Now. During the last few trading sessions, Mineralys Therapeutics Inc. (NASDAQ:MLYS) has seen positive momentum. On June 4, Goldman Sachs analyst Ri…
We recently compiled a list of the 8 Best Up and Coming Pharmaceutical Stocks to Buy Now. Mineralys Therapeutics, Inc. (NASDAQ:MLYS) is one of the best up and coming stocks on our list. TheFly reported on June 14 that MLYS presented new da…
David Malcom Rodman, Chief Medical Officer of Mineralys Therapeutics (NASDAQ:MLYS), reported the direct sale of 14,474 shares of Common Stock for a total transaction value of approximately $350,000, according to a SEC Form 4 filing. Transa…
Key Points The Chief Medical Officer of Mineralys Therapeutics reported selling 14,474 Common Stock shares across multiple transactions on June 15 and June 17, 2026, for a total value of approximately $350,000. This transaction represented…
Mineralys Therapeutics Inc. (NASDAQ:MLYS) is one of the best young stocks to invest in according to hedge funds. On June 3, Mineralys Therapeutics announced the pricing of an underwritten public offering of ~5.66 million shares of its comm…
(RTTNews) - Mineralys Therapeutics, Inc. (MLYS), reported positive post hoc data from Phase 3 Launch-HTN and Phase 2b Advance-HTN trials on the effect of Lorundrostat on heart failure risk biomarkers. Company Profile: Mineralys Therapeutic…
– Lorundrostat was associated with significant reductions in heart failure risk biomarkers in a proteomic analysis of data from participants with uncontrolled hypertension – – Coordinated reductions in biomarkers of fibrosis and heart fail…
Mineralys Therapeutics Inc. (NASDAQ:MLYS) is one of the 10 best AI driven biotech stocks to invest in. On June 3, Mineralys Therapeutics (NASDAQ:MLYS) shared a major update regarding its blood pressure drug, lorundrostat. The company is re…
Mineralys Therapeutics, Inc. RADNOR, Pa., June 08, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as c…
RADNOR, Pa., June 08, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD),…
Mineralys Therapeutics Inc. (NASDAQ:MLYS) is one of the 10 most promising mid-cap healthcare stocks according to hedge funds. On May 30, Mineralys Therapeutics Inc. (NASDAQ:MLYS) provided compelling data for the clinical efficacy of lorund…
What happened According to an SEC filing dated May 15, 2026, Velan Capital Investment Management LP sold 140,000 shares of Mineralys Therapeutics in the first quarter. The estimated value of the trade was $4.11 million, based on the quarte…
Key Points Reduced stake by 140,000 shares; estimated transaction value of $4.11 million based on quarterly average price Quarter-end position value fell by $5.18 million, reflecting both trading and stock price changes Post-trade holding:…
– Post hoc analysis from pivotal Launch-HTN trial shows statistically significant and clinically meaningful reductions in blood pressure in participants with chronic kidney disease – – In participants with chronic kidney disease and baseli…
Earnings Call Insights: Mineralys Therapeutics (MLYS) Q1 2026 MANAGEMENT VIEW * “During the first quarter, the FDA accepted the NDA for lorundrostat for the treatment of adult patients with hypertension in combination with other antihypert…
RADNOR, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), o…
Is MLYS a good stock to buy? We came across a bullish thesis on Mineralys Therapeutics, Inc. on Valueinvestorsclub.com by conway968. In this article, we will summarize the bulls’ thesis on MLYS. Mineralys Therapeutics, Inc.'s share was tra…
Jon Congleton, Chief Executive Officer of Mineralys Therapeutics(NASDAQ:MLYS), reported the sale of 75,000 shares in multiple open-market transactions on March 31 valued at approximately $1.97 million, according to an SEC Form 4 filing. Tr…
Mineralys Therapeutics Inc. (NASDAQ:MLYS) is one of the 7 best small-cap healthcare stocks to buy according to hedge funds. On March 13, Bank of America Securities maintained a Buy rating on Mineralys Therapeutics Inc. (NASDAQ:MLYS). The f…
Immunic appoints biopharmaceutical executive Jon Congleton to board Proactive uses images sourced from Shutterstock Immunic Inc (NASDAQ:IMUX, FRA:10VA) has announced the appointment of veteran biopharmaceutical executive Jon Congleton to i…
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied…
Mineralys Therapeutics Inc. (NASDAQ:MLYS) is one of the 11 Best Day Trading Stocks to Buy Now. Biopharmaceutical company Mineralys Therapeutics Inc. (NASDAQ:MLYS) scored a win on March 9th when it announced that the Food and Drug Administr…
Key Points Sphera Funds added 374,847 shares of Syndax Pharmaceuticals in the fourth quarter. The quarter-end position value rose by $10.06 million, reflecting both trading and price movement. The post-trade holding stood at 762,563 shares…
Key Points Sphera Funds bought 279,974 shares of Cogent Biosciences in the fourth quarter; the estimated transaction value was $7.87 million. The quarter-end position value increased by $12.03 million, reflecting both new shares and stock…
Shares of Mineralys Therapeutics MLYS were up 4.4% yesterday after the company announced that the FDA has accepted the new drug application (NDA) for its product candidate, lorundrostat, to treat adult patients with hypertension in combina…
(RTTNews) - Mineralys Therapeutics Inc. (MLYS) announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for Lorundrostat for the treatment of adult patients with hypertension in combination wit…
The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment…
RADNOR, Pa., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney…
Mineralys Therapeutics Inc. (NASDAQ:MLYS) is one of the best high short interest stocks with biggest upside potential. On January 6, Mineralys Therapeutics announced the late 2025 filing of its NDA for lorundrostat. The company highlighted…